BACKGROUND: A genetic deficiency in sepiapterin reductase leads to a combined deficit of serotonin and dopamine. The motor phenotype is characterized by a dopa-responsive fluctuating generalized dystonia-parkinsonism. The non-motor symptoms are poorly recognized. In particular, the effects of brain serotonin deficiency on sleep have not been thoroughly studied. OBJECTIVE: We examine the sleep, sleep-wake rhythms, CSF neurotransmitters, and melatonin profile in a patient with sepiapterin reductase deficiency. PATIENT: The patient was a 28-year-old man with fluctuating generalized dystonia-parkinsonism caused by sepiapterin reductase deficiency. METHODS: A sleep interview, wrist actigraphy, sleep log over 14 days, 48-h continuous sleep and core temperature monitoring, and measurement of CSF neurotransmitters and circadian serum melatonin and cortisol levels before and after treatment with 5-hydroxytryptophan (the precursor of serotonin) and levodopa were performed. RESULTS: Before treatment, the patient had mild hypersomnia with long sleep time (704 min), ultradian sleep-wake rhythm (sleep occurred every 11.8 +/- 5.3 h), organic hyperphagia, attentionlexecutive dysfunction, and no depression. The serotonin metabolism in the CSF was reduced, and the serum melatonin profile was flat, while cortisol and core temperature profiles were normal. Supplementation with 5-hydroxytryptophan, but not with levodopa, normalized serotonin metabolism in the CSF, reduced sleep time to 540 min, normalized the eating disorder and the melatonin profile, restored a circadian sleep-wake rhythm (sleep occurred every 24 +/- 1.7 h, P < 0.0001), and improved cognition. CONCLUSION: In this unique genetic paradigm, the melatonin deficiency (caused by a lack of its substrate, serotonin) may cause the ultradian sleep-wake rhythm.
BACKGROUND: A genetic deficiency in sepiapterin reductase leads to a combined deficit of serotonin and dopamine. The motor phenotype is characterized by a dopa-responsive fluctuating generalized dystonia-parkinsonism. The non-motor symptoms are poorly recognized. In particular, the effects of brain serotonin deficiency on sleep have not been thoroughly studied. OBJECTIVE: We examine the sleep, sleep-wake rhythms, CSF neurotransmitters, and melatonin profile in a patient with sepiapterin reductase deficiency. PATIENT: The patient was a 28-year-old man with fluctuating generalized dystonia-parkinsonism caused by sepiapterin reductase deficiency. METHODS: A sleep interview, wrist actigraphy, sleep log over 14 days, 48-h continuous sleep and core temperature monitoring, and measurement of CSF neurotransmitters and circadian serum melatonin and cortisol levels before and after treatment with 5-hydroxytryptophan (the precursor of serotonin) and levodopa were performed. RESULTS: Before treatment, the patient had mild hypersomnia with long sleep time (704 min), ultradian sleep-wake rhythm (sleep occurred every 11.8 +/- 5.3 h), organic hyperphagia, attentionlexecutive dysfunction, and no depression. The serotonin metabolism in the CSF was reduced, and the serum melatonin profile was flat, while cortisol and core temperature profiles were normal. Supplementation with 5-hydroxytryptophan, but not with levodopa, normalized serotonin metabolism in the CSF, reduced sleep time to 540 min, normalized the eating disorder and the melatonin profile, restored a circadian sleep-wake rhythm (sleep occurred every 24 +/- 1.7 h, P < 0.0001), and improved cognition. CONCLUSION: In this unique genetic paradigm, the melatonin deficiency (caused by a lack of its substrate, serotonin) may cause the ultradian sleep-wake rhythm.
Authors: Bernard Echenne; Agathe Roubertie; Birgit Assmann; Thomas Lutz; Johann M Penzien; Beat Thöny; Nenad Blau; Georg F Hoffmann Journal: Pediatr Neurol Date: 2006-11 Impact factor: 3.372
Authors: Elizabeth M Somerville; Julia M Horwood; Michelle D Lee; Guy A Kennett; Peter G Clifton Journal: Eur J Neurosci Date: 2007-05 Impact factor: 3.386
Authors: Marcel M Verbeek; Michel A A P Willemsen; Ron A Wevers; Aart J Lagerwerf; Nico G G M Abeling; Nenad Blau; Beat Thöny; Euthymia Vargiami; Dimitrios I Zafeiriou Journal: Mol Genet Metab Date: 2008-05-27 Impact factor: 4.797
Authors: Charles John Meliska; Luis Fernando Martínez; Ana María López; Diane Lynn Sorenson; Sara Nowakowski; Barbara Lockhart Parry Journal: Psychiatry Res Date: 2011-01-14 Impact factor: 3.222
Authors: Pearlynne L H Chong; Dea Garic; Mark D Shen; Iben Lundgaard; Amy J Schwichtenberg Journal: Sleep Med Rev Date: 2021-11-18 Impact factor: 11.609
Authors: Bill Campbell; Colin Wilborn; Lem Taylor; Mike Greenwood; Stephen Schmitz; Rick Collins; Jose Antonio; Paul La Bounty; Mike T Nelson; Tim N Ziegenfuss; Hector L Lopez; Jay R Hoffman; Jeffrey R Stout; Doug S Kalman; Richard B Kreider Journal: J Int Soc Sports Nutr Date: 2013-01-03 Impact factor: 5.150